Literature DB >> 24657533

Finding effective cancer therapies through loss of function genetic screens.

René Bernards1.   

Abstract

Intrinsic or acquired drug resistance often limits the success of cancer treatment. Loss of function genetic screens can help identify mechanisms of drug resistance and thereby deliver strategies to combat resistance. A further application of these genetic screens is the identification of drug targets whose inactivation is only effective in a specific context. This synthetic lethality approach enables the identification of drugs that act only in cancer cells having a cancer-specific mutation and the discovery of potent combination therapies. This review focuses on the question how functional genetic screens can help to improve the treatment of cancer.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24657533     DOI: 10.1016/j.gde.2013.11.007

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  10 in total

1.  Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.

Authors:  Elana P Simon; Catherine A Freije; Benjamin A Farber; Gadi Lalazar; David G Darcy; Joshua N Honeyman; Rachel Chiaroni-Clarke; Brian D Dill; Henrik Molina; Umesh K Bhanot; Michael P La Quaglia; Brad R Rosenberg; Sanford M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-21       Impact factor: 11.205

2.  CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes.

Authors:  Bastiaan Evers; Katarzyna Jastrzebski; Jeroen P M Heijmans; Wipawadee Grernrum; Roderick L Beijersbergen; Rene Bernards
Journal:  Nat Biotechnol       Date:  2016-04-25       Impact factor: 54.908

3.  High-throughput Functional Genomics Identifies Regulators of Primary Human Beta Cell Proliferation.

Authors:  Karine Robitaille; Jillian L Rourke; Joanne E McBane; Accalia Fu; Stephen Baird; Qiujiang Du; Tatsuya Kin; A M James Shapiro; Robert A Screaton
Journal:  J Biol Chem       Date:  2016-01-06       Impact factor: 5.157

4.  Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.

Authors:  Ghassan K Abou-Alfa; Robert Mayer; Alan P Venook; Allison F O'Neill; Muhammad S Beg; Michael LaQuaglia; Peter T Kingham; Rachel Kobos; Olca Basturk; Cameron Brennan; Adam Yopp; James J Harding; Stephen Leong; John Crown; Emir Hoti; Gregory Leonard; Michele Ly; Mikaela Bradley; Emily Valentino; David Markowitz; Alexander Zukiwski; Ken Ren; John D Gordan
Journal:  Oncologist       Date:  2020-03-10

5.  Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers.

Authors:  Joseph Rosenbluh; Johnathan Mercer; Yashaswi Shrestha; Rachel Oliver; Pablo Tamayo; John G Doench; Itay Tirosh; Federica Piccioni; Ella Hartenian; Heiko Horn; Lola Fagbami; David E Root; Jacob Jaffe; Kasper Lage; Jesse S Boehm; William C Hahn
Journal:  Cell Syst       Date:  2016-09-28       Impact factor: 10.304

6.  Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.

Authors:  Anjali Cremer; Jana M Ellegast; Gabriela Alexe; Elizabeth S Frank; Linda Ross; S Haihua Chu; Yana Pikman; Amanda Robichaud; Amy Goodale; Björn Häupl; Sebastian Mohr; Arati V Rao; Alison R Walker; James S Blachly; Federica Piccioni; Scott A Armstrong; John C Byrd; Thomas Oellerich; Kimberly Stegmaier
Journal:  Cancer Discov       Date:  2019-11-26       Impact factor: 38.272

7.  Cell Type-Specific and Inducible PTEN Gene Silencing by a Tetracycline Transcriptional Activator-Regulated Short Hairpin RNA.

Authors:  Shan Wang; Ting Wang; Tao Wang; Lintao Jia
Journal:  Mol Cells       Date:  2015-10-19       Impact factor: 5.034

8.  Key drivers of biomedical innovation in cancer drug discovery.

Authors:  Margit A Huber; Norbert Kraut
Journal:  EMBO Mol Med       Date:  2015-01       Impact factor: 12.137

9.  In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma.

Authors:  Lupeng Ye; Jonathan J Park; Matthew B Dong; Quanjun Yang; Ryan D Chow; Lei Peng; Yaying Du; Jianjian Guo; Xiaoyun Dai; Guangchuan Wang; Youssef Errami; Sidi Chen
Journal:  Nat Biotechnol       Date:  2019-09-23       Impact factor: 68.164

Review 10.  Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications.

Authors:  Valerie Jacquemin; Mathieu Antoine; Geneviève Dom; Vincent Detours; Carine Maenhaut; Jacques E Dumont
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.